Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Benitec Biopharma (BNTC) over the last 6 years, with Q2 2025 value amounting to $29000.0.

  • Benitec Biopharma's Change in Receivables fell 8352.27% to $29000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$197000.0, marking a year-over-year decrease of 21193.18%. This contributed to the annual value of -$197000.0 for FY2025, which is 21193.18% down from last year.
  • As of Q2 2025, Benitec Biopharma's Change in Receivables stood at $29000.0, which was down 8352.27% from -$226000.0 recorded in Q3 2024.
  • Benitec Biopharma's Change in Receivables' 5-year high stood at $176000.0 during Q2 2024, with a 5-year trough of -$226000.0 in Q3 2024.
  • In the last 4 years, Benitec Biopharma's Change in Receivables had a median value of $7000.0 in 2021 and averaged -$3142.9.
  • The largest annual percentage gain for Benitec Biopharma's Change in Receivables in the last 5 years was 75714.29% (2022), contrasted with its biggest fall of 77142.86% (2022).
  • Benitec Biopharma's Change in Receivables (Quarter) stood at -$7000.0 in 2021, then soared by 757.14% to $46000.0 in 2022, then tumbled by 591.3% to -$226000.0 in 2024, then surged by 112.83% to $29000.0 in 2025.
  • Its last three reported values are $29000.0 in Q2 2025, -$226000.0 for Q3 2024, and $176000.0 during Q2 2024.